Neuro-Oncology
NF2-related schwannomatosis
Dec. 13, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Chemotherapy neurologic complications …
- Updated 07.25.2024
- Released 12.10.1996
- Expires For CME 07.25.2027
Chemotherapy: neurologic complications
Introduction
Overview
Patients with cancer are living longer due to earlier diagnoses and steady improvement in treatments. Unfortunately, neurologic complications from chemotherapy remain a significant cause of morbidity and reduced quality of life, especially in long-term survivors. Novel therapies with small molecule tyrosine kinase inhibitors, monoclonal antibodies, immunotherapy with checkpoint inhibitors, CAR T-cell, and other cellular therapies have been associated with novel patterns of neurologic complications. Because treatment options for cancer therapy-induced neurologic complications are limited, awareness of common forms of neurotoxicity and early recognition of neurologic adverse events are important to prevent permanent neural injury. The authors review common neurologic complications of both conventional chemotherapy and novel anticancer therapies in this article.
Key points
|
• Neurologic complications from systemic anticancer therapies can have a significant impact on quality of life. | |
|
• Although neurotoxicities of conventional cytotoxic chemotherapy are widely known, targeted agents and novel immunotherapies are also associated with unique patterns of acute and delayed neurologic complications. | |
|
• Early recognition and prevention may help avoid permanent neurologic damage. |
Neurologic complications of chemotherapy
Neurologic complications of chemotherapy have been reported with increasing frequency in cancer patients with the use of more powerful and aggressive antineoplastic therapy, and because of improved outcomes and prolonged patient survival. Such complications may result from the direct toxic effects of the anti-cancer agent on the nervous system or indirectly from metabolic derangements, inflammatory responses, immune-mediated attack on the nervous system, disruption of the blood brain barrier, or cerebrovascular disorders induced by such anti-cancer drugs. Recognition of these complications is paramount because they may be confused with metastatic or recurrent disease and because discontinuation or dose reduction of the anti-cancer drug may prevent irreversible neural injury.
The neurologic complications of the more commonly used chemotherapeutic agents, antihormonal therapies, biological response modifiers, targeted molecular agents, immunotherapies, and novel forms of cellular and CAR-T cell therapies in cancer patients will be discussed. This topic is covered in detail in prior reviews (53; 171; 306; 58).
The neurologic complications of the most common systemic anti-cancer therapies are summarized in Table 1.
Table 1. Neurologic Complications of Systemic Anti-Cancer Therapies
|
Acute encephalopathy Dementia Cranial neuropathy Acute cerebellar syndrome Leukoencephalopathy |
Headache Aseptic meningitis Myelopathy Vasculopathy and stroke |
Seizures Visual loss Neuropathy Syncope |
Drugs that commonly cause neurotoxicity
Cisplatin. Cisplatin is an alkylating agent used to treat ovarian, testicular, cervical, bladder, lung, gastrointestinal, and head and neck cancers. It frequently causes neurotoxicity, especially peripheral neuropathy and ototoxicity.
Neuropathy. The main neurologic complication of cisplatin is a ganglionopathy affecting predominantly large diameter sensory neurons (132). Symptoms primarily result from injury to the dorsal root ganglion. The peripheral nerve may also be affected. The neuropathy is characterized by subacute development of nonpainful numbness and paresthesias in the extremities. Symptoms usually begin in the toes and then spread to the fingers and then, in ascending fashion, affect the proximal legs and arms. Proprioception is impaired and reflexes are lost, but pinprick sensation, temperature sensation, and power are often spared. Nerve conduction studies show decreased amplitude of sensory action potentials and prolonged sensory latencies consistent with a sensory axonopathy. Sural nerve biopsy may show both demyelination and axonal loss.
The main differential diagnoses include paraneoplastic neuropathies and neuropathies associated with autoimmune disorders such as in Sjögren syndrome. Paraneoplastic neuropathies tend to involve all sensory fibers and may progress despite discontinuation of cisplatin. Some patients test positive for antineuronal antibodies (anti-Hu) in serum. Patients with autoimmune neuropathies often have clinical features of the underlying connective tissue disease, and autoimmune antibodies are usually present in serum and cerebrospinal fluid.
There is marked individual susceptibility to the development of cisplatin-induced neuropathies (177). Typically, neuropathies develop in patients following cumulative doses of cisplatin greater than 400 mg/m2 (28). Increased dose intensity of cisplatin administration does not appear to enhance the severity of the neuropathy (115; 116). Patients with mild neuropathies can continue to receive full doses of cisplatin. Once the neuropathy becomes more severe and begins to interfere with neurologic function, the clinician must decide whether to continue with therapy and risk potentially disabling neurotoxicity, reduce the dose of drug, or discontinue the drug and replace it with less neurotoxic agents. The most appropriate course of action varies with each patient and should consider various factors, such as the severity of the neuropathy and the availability of less neurotoxic alternatives. After cessation of chemotherapy, the neuropathy usually continues to deteriorate for several months in 30% of patients, the so-called coasting phenomenon (258). Most patients eventually improve, although recovery is often incomplete (28).
Many agents have been tested for the prevention or treatment of chemotherapy-induced peripheral neuropathy, including neuropathy caused by cisplatin (04). The 2020 American Society for Clinical Oncology Clinical Practice guideline on chemotherapy-induced peripheral neuropathy does not recommend any specific agents for the prevention of neuropathy based on the paucity of high-quality data and lack of sufficient evidence (163). Regarding the treatment of existing chemotherapy-induced peripheral neuropathy, the best available data support a moderate recommendation for treatment with duloxetine (260; 163).
Cranial neuropathies. Cisplatin may cause ototoxicity, leading to high-frequency sensorineural hearing loss and tinnitus. The toxicity is due to peripheral receptor (hair) loss in the organ of Corti and is related to drug dose (184). Audiometric hearing loss is present in 74% to 88% of patients receiving cisplatin, and symptomatic hearing loss occurs in 16% to 20% of patients. Cranial irradiation probably increases the likelihood of significant hearing loss in patients also treated with platinum drugs. The hearing loss tends to be worse in children, although they have a slightly greater ability to improve after the drug has been discontinued. Cisplatin may also cause a vestibulopathy, resulting in ataxia and vertigo, and can be associated with hearing loss. Previous use of aminoglycosides may exacerbate the degree of vestibulopathy (20; 184). Intraarterial infusion of cisplatin for head and neck cancer resulted in cranial palsies in approximately 6% of patients (83). Intracarotid infusion of cisplatin may also cause ocular toxicity, although these complications rarely occur after intravenous administration of the drug (146). They include retinopathy, papilledema (200), optic neuritis (200), and disturbed color perception due to dysfunction of retinal cones (291). Other complications of intraarterial cisplatin include headaches, confusion, and seizures (271). Fortunately, such treatments are rarely considered nowadays.
Myelotoxicity (Lhermitte sign). This symptom, characterized by paresthesias localizing to the upper spine, back, and extremities with neck flexion, is seen in 20% to 40% of patients receiving cisplatin. Patients tend to develop this symptom after several weeks or months of treatment. Neurologic exam and MRI scans are usually normal and the Lhermitte sign often resolves spontaneously several months after the drug has been discontinued. It is thought to result from transient demyelination of the posterior columns or from Wallerian degeneration of the central projections of the dorsal root ganglion (132). Very rarely, a true myelopathy has been reported (53).
Less common complications. Infrequently, cisplatin produces encephalopathy, possibly associated with seizures and focal neurologic symptoms, including cortical blindness (53). The encephalopathy is associated with reversible abnormalities in white matter tracts of the occipital, parietal, and frontal lobes and clinically resembles the reversible posterior leukoencephalopathy syndrome. The encephalopathy tends to be more common after intraarterial administration of the drug (191). It needs to be distinguished from a metabolic encephalopathy secondary to water intoxication caused by excessive hydration, or from renal impairment, hypomagnesemia, hypocalcemia, and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) that may follow treatment with cisplatin. Cisplatin can also cause vascular toxicity, resulting in ischemic infarction (87; 125). One case of acute corpus callosum hemorrhages was reported following combination treatment with cisplatin, ifosfamide, and etoposide (60). Other rare complications include taste disturbance and a myasthenic syndrome (53). Interestingly, cisplatin may cause long-term adverse effects on cognitive function (276). The exact mechanisms on cognitive function are unclear. Cisplatin may be retained in tissues and plasma even for years after cessation of treatment (91; 27). Long-term toxicity and cognitive impairment may be related to damage to neural progenitor cell populations in the nervous system critically important in maintenance of brain plasticity, memory function, and subcortical network systems (59; 63).
Methotrexate and other antifolate agents. Methotrexate is a dihydrofolate reductase inhibitor used in the treatment of a wide range of cancers, including leukemias, lymphomas, choriocarcinoma, breast cancer, lung cancer, sarcomas, central nervous system lymphoma, and leptomeningeal metastases. The degree of neurotoxicity is determined by the dosage, its route of administration, and the use of other concomitant therapeutic modalities with overlapping neurotoxicities, including other chemotherapeutic agents and irradiation.
Intrathecal methotrexate toxicity. Aseptic meningitis is the most common neurotoxicity associated with intrathecal methotrexate therapy (93; 171). This occurs in approximately 10% of patients, although some series have reported incidences as high as 50%. Symptoms usually start 2 to 4 hours after the drug is injected and can last for 12 to 72 hours. Neurotoxicity resulting in aseptic meningitis is characterized by headaches, nuchal rigidity, back pain, nausea, vomiting, fever, and lethargy and is indistinguishable from other types of chemical meningitis. The CSF shows pleocytosis and elevated protein. Although symptoms are self-limiting in most patients, there have been reports of delayed, disseminated, necrotizing leukoencephalopathy several months after treatment, especially in patients receiving repeated and high cumulative doses of intrathecal methotrexate combined with whole-brain radiotherapy (24). Aseptic meningitis can be prevented to some extent by injecting methotrexate together with hydrocortisone or by using oral corticosteroids (92). Some patients who developed aseptic meningitis have been subsequently retreated with methotrexate without problems.
Transverse myelopathy, a less common complication of intrathecal methotrexate, is characterized by back or leg pain followed by paraplegia, sensory loss, and sphincter dysfunction. Symptoms usually occur within hours to few days after treatment but may be delayed in onset up to several weeks after treatment. Most affected patients will show clinical improvement, but the extent of recovery is variable (84). This complication is more common in patients receiving concurrent radiotherapy or frequent treatments of intrathecal methotrexate.
Acute and subacute neurotoxicity and leukoencephalopathy with stroke-like focal deficits may be associated with abnormal MRI findings, such as diffusion-weighted imaging hyperintensities that may not be confined to typical vascular territories (10). Diffusion-weighted imaging abnormalities can be seen in subcortical or deep periventricular white matter, corpus callosum, cortex, cerebellum, and thalamus (233; 77; 145; 109; 304; 13; 32). It has been suggested that DWI changes in methotrexate-associated neurotoxicity represent reversible cerebral dysfunction with associated cytotoxic edema and metabolic derangement rather than true ischemic structural injury (233; 109). Accidental overdosage of methotrexate (more than 500 mg) has resulted in myelopathy and encephalopathy with fatal outcome. The use of rapid CSF drainage, ventriculo-lumbar perfusion, high-dose leucovorin, and alkaline diuresis has allowed some patients to survive (262). Cases of irreversible cerebellar atrophy following intrathecal methotrexate have also been described (174).
Weekly low-dose methotrexate neurotoxicity. Up to 20% of patients receiving weekly low-dose methotrexate (eg, for rheumatological conditions) may experience headaches, dizziness, dysphoria, and subtle cognitive impairment (290). Both renal insufficiency and older age are associated risk factors for neurotoxicity. Oral methotrexate may also result in acute focal neurologic deficits (07) and abnormal imaging findings, consistent with reversible posterior leukoencephalopathy (222). Symptoms usually resolve when methotrexate is discontinued. Neurotoxicity characterized by dysarthria, gait dysfunction, dysmetria, and weakness has been described after low-dose subcutaneous methotrexate injection for rheumatoid arthritis. Symptoms were reversible, however, and resolved after discontinuation of treatment (174).
High-dose methotrexate neurotoxicity. High-dose methotrexate may cause acute, subacute, and chronic neurotoxicity.
Acute neurotoxicity following high-dose methotrexate is characterized by somnolence, confusion, and seizures within 24 hours of treatment. Symptoms usually resolve spontaneously without sequelae, and patients can often continue to receive this drug in the future (53). Weekly treatments with high-dose methotrexate may produce a subacute "stroke-like" syndrome characterized by transient focal neurologic deficits, confusion, and occasionally seizures (285). Typically, the disorder develops several days after high-dose methotrexate, lasts 15 minutes to 72 hours, and resolves spontaneously without sequelae. Neuroimaging and CSF studies are usually normal, but EEG may show diffuse slowing. Methotrexate may be subsequently administered without the encephalopathy recurring. The pathogenesis of this syndrome is unknown but may be related to impaired cerebral glucose metabolism.
Leukoencephalopathy. The major delayed complication of methotrexate therapy is leukoencephalopathy (58; 135). Although this syndrome may be produced by intrathecal or high-dose systemic methotrexate alone, it is exacerbated by radiotherapy, especially if radiotherapy is administered before or during methotrexate therapy. The clinical features are characterized by the gradual development of cognitive impairment months or years after treatment with methotrexate. The clinical picture ranges from mild learning disabilities to severe progressive dementia associated with somnolence, seizures, ataxia, and hemiparesis (44). CT and MRI scans show diffuse white matter lesions and progressive cerebral atrophy (135). Histopathologic evaluations of affected brain lesions range from loss of oligodendrocytes and gliosis to a picture of necrotizing leukoencephalopathy (113). The clinical course is variable.
Many patients stabilize or improve after discontinuation of methotrexate, but the course is progressive in some patients and may result in death. No effective treatment is available. The cause of leukoencephalopathy is poorly understood. Preclinical studies suggest that methotrexate activates microglia and astrocytes in white matter, which ultimately depletes myelin-forming cells, resulting in a persistent deficit in myelination (90). Studies also suggest that genetic polymorphisms for methionine metabolism, which is required for myelination, may constitute a risk factor for methotrexate-associated neurotoxicity (160; 186; 135). It is likely that cranial irradiation either potentiates the toxic effects of methotrexate or disrupts the blood-brain barrier, allowing high concentrations of methotrexate to enter the brain parenchyma. It is also seen after high dose intravenous methotrexate chemotherapy.
Pemetrexed is a powerful antifolate that is used alone or in combination with other chemotherapeutic agents such as in malignant mesothelioma and non-small cell lung cancer. It causes a neuropathy that can be prophylactically treated with vitamin B12 and folate supplementation (34; 148).
Oxaliplatin. Oxaliplatin is a third-generation platinum complex that has activity against cisplatin-resistant tumor cells. It is mostly used to treat colorectal cancer. An acute transient neuropathy occurs in most patients and is characterized by cold sensitivity, throat discomfort, discomfort swallowing cold liquids, and muscle cramps (163). Symptoms can occur at the time of infusion but typically peak 2 to 3 days after infusion. This complication occurs more frequently at doses of 130 mg/m2 (85). A sensory neuropathy is considered a dose-limiting toxicity, which occurs in up to 50% to 90% of patients (144; 140; 151). Neuropathies tend to be associated with increased cumulative doses (206) but are rarely severe at conventional doses and tend to improve after therapy is discontinued (73; 88). In some patients, oxaliplatin-induced neuropathy can worsen for 2 to 3 months after cessation of therapy (so-called coasting phenomenon) before eventually improving (163). Approaches used to prevent or minimize oxaliplatin neurotoxicity include temporarily pausing oxaliplatin, dose reduction, and lengthening the duration of infusion. Calcium and magnesium infusions (85; 117; 118) were initially reported to be beneficial for the prevention of oxaliplatin-induced peripheral neuropathy. However, a phase 3 randomized, placebo-controlled trial of intravenous calcium and magnesium with oxaliplatin demonstrated no benefit in preventing or diminishing the severity of acute or chronic neurotoxicity from oxaliplatin (164).The 2020 American Society for Clinical Oncology Clinical Practice guideline on chemotherapy-induced peripheral neuropathy so far does not recommend any agents for the prevention of oxaliplatin-induced neuropathy, but it provides a recommendation for the treatment of neuropathy with duloxetine (163).
Taxanes: paclitaxel and docetaxel. Taxanes are used to treat a variety of cancers including ovary, breast, and non-small cell lung cancers. They contain a plant alkaloid that inhibits microtubule function, leading to mitotic arrest (236). Paclitaxel produces a dose-limiting peripheral neuropathy, which occurs in approximately 60% of patients receiving 250 mg/m2 (161; 182). Toxicity is predominantly characterized by a symmetric, sensory axonal neuropathy affecting both large and small fibers (09). Symptoms usually begin after 1 to 3 weeks of treatment. Patients develop burning paresthesias of the hands and feet and loss of reflexes. The neuropathy often does not progress despite continued treatment, and there have even been reports of patients clinically improving with continuing therapy. Some patients develop a pain syndrome primarily involving the trunk and hips beginning 2 to 3 days after a course of paclitaxel lasting 2 to 4 days; although previously labeled as myalgias and arthralgias, newer data suggest that these symptoms represent an acute neuropathy (163). Less commonly, paclitaxel can result in motor neuropathies that predominantly affect proximal muscles (82), perioral numbness, and autonomic neuropathies (236). Rarely, paclitaxel causes visual scotomas, optic neuropathies, seizures, vocal cord palsies, transient encephalopathies (210; 45), or phantom limb pain in patients with prior amputation (138). Neuropathies are less common with docetaxel, but some patients develop sensory and motor neuropathies similar to the effects of paclitaxel (82; 190). Docetaxel can occasionally produce a Lhermitte sign (278). High-dose paclitaxel (greater than 600 mg/m2) can lead to an acute encephalopathy and subsequent death between 7 and 23 days after treatment (193; 99). The neurotoxic effects of paclitaxel and docetaxel are increased when combined with cisplatin (116; 115). Liposomal encapsulation of paclitaxel may reduce the incidence of neurotoxicity (275). The 2020 American Society for Clinical Oncology Clinical Practice guideline on chemotherapy-induced peripheral neuropathy does not recommend any agents for the prevention of taxane-induced neuropathy but does provide moderate recommendation for treatment of established neuropathy with duloxetine (260; 163).
Vinca alkaloids: vincristine and vinorelbine. Vincristine is a vinca alkaloid used to treat many cancers, including leukemia, lymphomas, sarcomas, and brain tumors. Its main toxicity is an axonal neuropathy resulting from disruption of the microtubules within axons and interference with axonal transport (132). The neuropathy involves both sensory and motor fibers, although small sensory fibers are especially affected. Virtually all patients have some degree of neuropathy, which is considered a dose-limiting toxicity (49). The clinical features resemble those of other axonal neuropathies such as diabetic neuropathies. The earliest symptoms are usually paresthesias in the fingertips and feet and muscle cramps. These symptoms may occur after several weeks of treatment, or even after the drug has been discontinued, and progress for several months before improving. Children tend to recover more quickly than adults. Initially, objective sensory findings tend to be relatively minor compared to the symptoms, but loss of ankle reflexes is common. Occasionally there may be profound weakness, with bilateral foot and wrist drop and loss of all sensory modalities. Severe neuropathies are more likely to develop in older patients who are cachectic, patients who have received prior radiation to the peripheral nerves or concomitant hematopoietic colony-stimulating factors (289), and those who have preexisting neurologic conditions affecting the peripheral nervous system, such as Charcot-Marie-Tooth (119; 288). The severity of vincristine-related peripheral neuropathy is cumulative, occurring in most patients after a total dose of more than 4 mg/m2 (132).
Patients with mild neuropathies can receive full doses of vincristine, but when the neuropathies increase in severity and interfere with neurologic function, reduction in dose or discontinuation of the drug may be necessary. Although symptoms often improve over months after dose reduction or discontinuation of vincristine, the coasting phenomenon can be seen in up to 30% of patients. Vincristine may also cause focal neuropathies (80; 53). Although anecdotal reports indicate that glutamine may help some patients with vincristine neuropathy, there is generally no effective treatment (80). Rarely, vincristine can cause a fulminant neuropathy with severe quadriparesis that mimics Guillain-Barré syndrome (185; 96).
Autonomic neuropathy is common in patients receiving vincristine. Abdominal pain and constipation occur in almost 50% of patients. A paralytic ileus may occur. Because of the known adverse effects on the gastrointestinal system, patients receiving vincristine should take prophylactic stool softeners and laxatives. Less commonly, patients may develop impotence, postural hypotension, and atonic bladders.
Cranial neuropathies may occasionally be seen with vincristine. The most common nerve to be involved is the oculomotor nerve, resulting in ptosis and ophthalmoplegia. Other nerves that may be involved include the recurrent laryngeal nerve, optic nerve, facial nerve, and the auditory vestibular system. Vincristine may also cause retinal damage and night blindness. Some patients may experience jaw and parotid pain.
CNS complications are rare, as vincristine poorly penetrates the blood-brain barrier. Rarely, vincristine may cause the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), resulting in hyponatremia, confusion, and seizures (229). CNS complications unrelated to SIADH may also occur. These include seizures, encephalopathy, reversible posterior leukoencephalopathy (202; 104), transient cortical blindness, ataxia, athetosis, and parkinsonism (107; 53).
The related vinca alkaloids vindesine, vinblastine, and vinorelbine tend to have less frequent neurotoxicity (267). This may be related to differences in lipid solubility, plasma clearance, terminal half-life, and sensitivities of axoplasmic transport (80; 53). Vinorelbine is a semisynthetic analogue of vinblastine that is being increasingly used for patients with breast and lung cancer. Like vincristine, vinorelbine inhibits microtubule assembly but has less affinity for neural tissue and, therefore, was predicted to be less neurotoxic. Vinorelbine use is associated with mild paresthesias in about 20% of patients (237). Severe neuropathy is rare but appears to be more common in patients treated previously with paclitaxel (74; 194).
Drugs that occasionally cause neurotoxicity
Asparaginase. L-asparaginase is used mainly to treat acute lymphocytic leukemia. Direct neurotoxicity with L-asparaginase at conventional doses is rare, as it does not readily cross the blood-brain barrier. However, it may affect coagulation, causing hemorrhagic and thrombotic complications, including central venous thrombosis and cerebral infarction (127; 75; 72). These complications typically occur after several weeks of treatment. Patients may present with headaches, seizures, and focal neurologic deficits. There may be papilledema resulting from increased intracranial pressure. MRI may show venous infarction, which is often hemorrhagic, and MR venography demonstrates decreased or absent flow in the affected sinus (248; 155). Treatment is controversial, but anticoagulation with heparin is generally recommended. At high doses, asparaginase may also produce a reversible encephalopathy syndrome (221). Seizures have been reported as the single manifestation of CNS toxicity (106). The related PEG-asparaginase has a similar neurotoxicity profile to L-asparaginase (98).
Cytosine arabinoside. Cytosine arabinoside (cytarabine, Ara-C) is a pyrimidine analogue used in the treatment of leukemias and lymphomas. Blood-brain barrier penetration is good after intravenous application, and about 50% of plasma Ara-C levels are detected in CSF. High doses (1 to 3 g/m2 every 12 to 24 hours) can cause an acute cerebellar syndrome in up to 25% of patients (294; 124; 114). Patients above the age of 40 with abnormal liver or renal function or underlying neurologic dysfunction or who are receiving more than 30 g of the drug are more likely to develop cerebellar toxicity and cerebellar function will need to be closely monitored in patients after treatment. Typically, the patients develop somnolence and occasionally encephalopathy 2 to 5 days after treatment. Subsequently, patients develop cerebellar signs. These range from mild ataxia to severe truncal ataxia with inability to sit or walk unassisted (12). In addition to cerebellar syndromes, Ara-C may cause seizures.
Although it has been shown that Ara-C is preferentially toxic to cerebellar Purkinje cells and cerebellar granule neurons (294; 70; 51), Ara-C also targets both lineage-committed progenitor cell populations and nondividing oligodendrocytes, which are the myelin-forming cells of the central nervous system (59). Thus, some of the neurotoxic adverse reactions and symptoms seen in patients may be a direct consequence of both oligodendrocyte toxicity and impairment of progenitor self-renewal in the CNS.
Neuroimaging studies may show T2/FLAIR hyperintensities, white matter abnormalities, and eventually cerebellar atrophy (58; 295). MR imaging in patients with acute toxicity may demonstrate multifocal T2/FLAIR hyperintensities involving both gray and white matter and may resemble a picture of reversible posterior leukoencephalopathy syndrome (242). No specific treatment of acute CNS toxicity is available, but the drug should be discontinued immediately. In some patients, the cerebellar syndrome resolves spontaneously but it is permanent in others. Avoidance of very high doses of the drug, especially in patients with renal impairment, has led to a decline in the incidence of this syndrome (261; 159).
Other neurotoxic adverse effects seen after high-dose cytosine arabinoside include peripheral neuropathies resembling Guillain-Barré syndrome, brachial plexopathy, encephalopathy, lateral rectus palsy, and extrapyramidal syndromes (211; 198; 214; 199; 241; 53).
Intrathecal administration of cytosine arabinoside is used to treat leptomeningeal metastases or in aggressive forms of leukemia and lymphoma. It can cause a transverse myelopathy, similar to the clinical syndrome reported after intrathecal methotrexate (69; 149). Other rare CNS toxicities include aseptic meningitis, encephalopathy, headaches, posterior leukoencephalopathy, and seizures (111; 53). The incidence of aseptic meningitis may significantly increase after use of a sustained-release preparation of cytosine arabinoside (130), but this formulation is no longer available for commercial use. CNS complications with intrathecal Ara-C may partially be prevented by prophylactic treatment with corticosteroids (93).
Eribulin. Eribulin is a non-taxane microtubule dynamics inhibitor used to treat metastatic breast cancer (97). In clinical trials, peripheral neuropathy has been reported in 30.6% of patients, with 6.6% experiencing severe neuropathy and 4.7% discontinuing eribulin due to this neurotoxicity. Eribulin-related neuropathy has a cumulative effect.
5-Fluorouracil. 5-Fluorouracil is a fluorinated pyrimidine that disrupts DNA synthesis by inhibiting thymidylate synthetase. It is used to treat many cancers, including colon and breast, as well as head and neck cancers.
An acute cerebellar syndrome may occur in approximately 5% of patients (226; 211). This usually begins weeks or months after treatment and is characterized by the acute onset of ataxia, dysmetria, dysarthria, and nystagmus. The drug should be discontinued in any patient who develops a cerebellar syndrome. With time, these symptoms can resolve. The development of a cerebellar syndrome may be explained partly by the fact that 5-fluorouracil readily crosses the blood-brain barrier. Highest concentrations are found in the cerebellum.
In rare cases, 5-fluorouracil may cause acute and subacute encephalopathies, optic neuropathy, eye movement abnormalities, focal dystonia, cerebrovascular disorders, extrapyramidal syndromes (80; 26), peripheral neuropathy (263), or seizures (212). Patients with decreased dihydropyrimidine dehydrogenase activity are at an increased risk for developing severe neurologic toxicity following 5-fluorouracil (268).
The combination of 5-fluorouracil and levamisole used to treat colorectal cancer has been rarely associated with the development of an encephalopathy and ataxia resulting from multifocal demyelinating lesions in the periventricular white matter (120). The cause of these lesions is unknown, and they usually improve with steroids and discontinuation of the drugs. A similar syndrome of multifocal leukoencephalopathy has also been reported after capecitabine, a 5-fluorouracil prodrug (192; 283). MRI may show increased signals on T2/FLAIR and diffusion-weighted imaging (DWI) sequences in cerebral white matter tracts. The importance of recognizing this syndrome is that the cerebral lesions may be mistaken for brain metastases.
Experimental studies have shed further light on the cell-biological basis of 5-fluorouracil-related short-term and long-term toxicity. 5-fluorouracil appears to be particularly harmful to oligodendrocyte precursor cells, and long-term adverse effects may be explained by a disruption of the integrity of myelinated fiber tracts and delayed demyelination (108).
The administration of 5-fluorouracil with other drugs may increase the incidence of neurotoxicity. For example, the coadministration of 5-fluorouracil with allopurinol, N-phosphonoacetyl-L-aspartate, doxifluridine, carmofur, or tegafur has been reported to result in increased incidences of encephalopathies and cerebellar syndromes (80; 195).
Ifosfamide. This is an analog of cyclophosphamide, with similar systemic toxicities. Unlike cyclophosphamide, it is associated with encephalopathy in approximately 20% of patients (178; 302; 216; 03; 33). The encephalopathy begins hours or days after administration of the drug and usually resolves completely after several days. This form of encephalopathy is thought to result from accumulation of chloroacetaldehyde, one of the breakdown products of ifosfamide. Patients at increased risk for the encephalopathy include those with renal dysfunction, low serum albumin, prior treatment with cisplatin, and previous encephalopathy with ifosfamide (178; 216; 225). There have been reports that methylene blue may be useful in preventing or treating ifosfamide encephalopathy by inhibiting monoamine oxidases (02; 209; 277; 207). For most patients, no specific treatment is necessary, and the encephalopathy usually improves with time. Rarely, ifosfamide can cause seizures, cerebellar ataxia, weakness, cranial nerve dysfunction, neuropathies, or extrapyramidal syndrome (78; 217; 52). Notably, toxicity can be of varying degrees, from mild to transient and even fatal (56).
Nitrosoureas. Nitrosoureas (BCNU, CCNU, PCNU, ACNU) are lipid soluble alkylating agents that rapidly cross the blood-brain barrier and are commonly used to treat brain tumors, melanoma, and lymphoma. These drugs are considered to have little neurotoxicity when used intravenously or orally and at conventional doses, although confusion, lethargy, and ataxia may occur. In contrast, high-dose intravenous BCNU used in the setting of autologous bone marrow transplantation can cause encephalomyelopathy and seizures, which develop over a period of weeks to months after the administration of the drug.
Historically used intraarterial BCNU produces ocular toxicity and neurotoxicity in 30% to 48% of patients (255; 256). It is uncommon to use intraarterial administration of this drug in contemporary times. Intravenous administration or direct intratumoral administration via polymer wafers impregnated with BCNU are still used. Patients often complain of headache and eye and facial pain. Retinopathy and blindness may occur. The neurotoxicity further includes significant confusion, seizures, and progressive neurologic deficits. Imaging and pathologic studies show findings similar to what can be seen in radiation necrosis confined to the vascular territory perfused by the BCNU (53). Concurrent radiotherapy increases the neurotoxicity of intraarterial BCNU (235). Injection of the drug above the origin of the ophthalmic artery reduces the incidence of ocular toxicity but increases neurotoxicity. Although the detailed pathophysiology of nitrosourea-associated CNS toxicity is poorly understood, BCNU appears to be directly toxic to oligodendrocytes and neural progenitor cells. Even exposure to sublethal doses significantly impairs key progenitor cell functions of proliferation and differentiation. In animal models, repetitive exposure was associated with long-term impairment of neuroglial progenitor cell proliferation in of the CNS (59). Consequently, it has been suggested that toxicity to progenitor cells and oligodendrocytes constitutes the main cellular basis for CNS toxicity, including leukoencephalopathy and delayed progressive cognitive impairment (59; 68).
Procarbazine. Procarbazine is a weak monoamine oxidase inhibitor that probably acts as an alkylating agent. It is used to treat lung carcinoma, lymphoma, and brain tumors. At normal oral doses it can cause a mild reversible encephalopathy syndrome and neuropathy, and rarely psychosis and stupor (80; 53). The incidence of encephalopathy may be increased in patients receiving “high-dose” procarbazine, CCNU, and vincristine chemotherapy for malignant gliomas (215). Procarbazine also potentiates the sedative effects of narcotics, phenothiazines, and barbiturates. Intravenous and intracarotid procarbazine can produce a severe form of encephalopathy.
Thalidomide. Thalidomide is a sedative and hypnotic agent, which was initially introduced in Europe in 1954, but was withdrawn in 1961 due to the high incidence of limb malformations in children of women exposed to the drug. Thalidomide also exhibits immunomodulatory and antiangiogenic mechanisms. The FDA approved thalidomide for the treatment of multiple myeloma in 2006. The most common side effect is a sensory (often painful) peripheral neuropathy, which develops in up to 75% of patients who receive a prolonged course of thalidomide (39; 128; 274; 183; 213; 143). This may improve slightly with discontinuation of the drug, although recovery is often slow and incomplete. Another common side effect is somnolence, affecting 43% to 55% of patients. Many patients develop tachyphylaxis to this side effect with decreased somnolence after 2 or 3 weeks. Lenalidomide is an analog of thalidomide and is associated with a lower incidence of peripheral neuropathy (175).
Drugs that rarely cause neurotoxicity
Anthracycline antibiotics (doxorubicin, daunorubicin, idarubicin, mitoxantrone). Doxorubicin is an anthracycline antibiotic used to treat a variety of cancers including hematologic malignancies and breast cancer. It can cause arrhythmias and cardiomyopathies, which in turn can result in cerebrovascular complications (247). Doxorubicin in combination with cyclosporine can lead to coma and death (204). Apart from accidental intrathecal injection, which can cause severe myelopathy and encephalopathy, these agents have little overall neurotoxicity (53). Idarubicin and daunorubicin appear to be much less neurotoxic than doxorubicin, and nervous system toxicity may only be seen after high-dose applications or when administered in combination with other neurotoxic agents. Mitoxantrone has no known neurotoxicity when given intravenously but may produce radiculopathy and myelopathy when given intrathecally (105).
Bleomycin sulfate. Bleomycin inhibits DNA synthesis by binding to guanosine and cytosine through intercalation mechanisms as well as by cleaving DNA strands via free radical production. It is used to treat lymphoma, Hodgkin disease, testicular cancer, and head and neck cancer. When used in combination with cisplatin, it can produce cerebral infarction (65; 60).
Busulfan. This is an alkylating agent used in patients with leukemia. It has little neurotoxicity at standard doses, but high-dose therapy can cause seizures (280; 150).
Capecitabine. This is metabolized to its cytotoxic form, 5-FU, by the enzyme thymidine phosphorylase and is used to treat breast and gastrointestinal malignancies. Neurologic complications are uncommon, but some patients experience paresthesias, headaches, and cerebellar symptoms. Several cases of neuropathies have been described (240). There have also been case reports of capecitabine-induced multifocal leukoencephalopathy (192; 283). Capecitabine leukoencephalopathy has an earlier onset than 5-FU leukoencephalopathy, and the MRI changes are nonenhancing (283). Delayed leukoencephalopathy with stroke-like presentation has been described following capecitabine exposure (10).
Carboplatin. Carboplatin is an alkylating agent used for ovarian, cervical, testicular, lung, and head and neck cancers. Unlike cisplatin, peripheral neuropathy and CNS toxicity occur only rarely at conventional doses. However, a severe neuropathy can develop after high-dose carboplatin (110). Intraarterial carboplatin may produce stroke-like syndromes (286) and retinal toxicity (265). Carboplatin may be associated with peripheral nervous system toxicity, including ototoxicity and neuropathy. Toxicity may present as a pure sensory and painful neuropathy, as it also is seen with cisplatin and oxaliplatin (219). Neurotoxicity depends on the total cumulative dose and other predisposing factors, such as diabetes mellitus, alcohol use, or inherited genetic forms of neuropathy. Overall, carboplatin-associated neuropathy is considered much less frequent than cisplatin-associated neuropathy.
2-chlordeoxyadenosine (cladribine). This drug inhibits DNA polymerase and ligase and ribonucleotide reductase, resulting in DNA strand breakage. It is used for hairy cell leukemia, low-grade non-Hodgkin lymphoma, chronic myelogenous leukemia, and Waldenstrom macroglobulinemia. It has little neurotoxicity at conventional doses but can produce headache, dizziness, and paraparesis at high doses (40).
Chlorambucil. Chlorambucil is an alkylating agent used to treat chronic lymphocytic leukemia, low-grade non-Hodgkin lymphomas, Hodgkin disease, ovarian cancer, Waldenstrom macroglobulinemia, polycythemia vera, trophoblastic neoplasms, and nephrotic syndrome. It usually has little neurotoxicity at lower doses but can cause encephalopathy, myoclonus (299), and seizures when taken in very high doses (243).
Etoposide. This is a topoisomerase-II inhibitor used in the treatment of lung cancer, germ cell tumors, and refractory lymphoma. It is generally well tolerated, even at high doses. Rarely, it can cause a peripheral neuropathy, mild disorientation, seizures, transient cortical blindness, or optic neuritis (80).
Fludarabine. Fludarabine is an inhibitor of DNA polymerase and ribonucleotide reductase. It is used to treat chronic lymphatic leukemia, macroglobulinemia, and indolent lymphomas. It has been increasingly used in recent years as part of a lymphodepleting regimen prior to CAR-T cell therapy (167). Neurotoxicity is uncommon, but fludarabine can cause headaches, somnolence, confusion, and paresthesias at low doses (43; 53), and a delayed progressive encephalopathy with seizures, visual loss, paralysis, and coma at high doses (287). There have been some reports about severe leukoencephalopathy following fludarabine with lethal outcome (230; 181; 296). Fludarabine may increase the risk of JC virus associated multifocal leukoencephalopathy (245; 282; 141). Cladribine (2-chlordeoxyadenosine), a related drug used for Waldenstrom macroglobulinemia, can produce paraparesis at high doses (204).
Cyclophosphamide. Cyclophosphamide at standard doses has little neurotoxicity. High-dose cyclophosphamide may produce reversible visual blurring, dizziness, and confusion (53). Its metabolite, 4-hydroperoxy-cyclophosphamide, has been used experimentally as intrathecal therapy for leptomeningeal metastases. At high doses it can cause lethargy and seizures (211). Rarely, a reversible posterior leukoencephalopathy syndrome (104) or a necrotizing leukoencephalopathy syndrome, which can be fatal, have been reported following the cyclophosphamide-containing CHOP regimen for non-Hodgkin lymphoma (35; 21).
Dacarbazine. Dacarbazine mainly is used to treat melanoma. Neurotoxicity is very rare, but seizures, encephalopathy, and dementia have been reported (208).
Estramustine. Estramustine has estrogenic effects and causes dissociative effects on microtubules leading to metaphase arrest. It is used to treat advanced prostate carcinoma. It has been associated with headaches and stroke (40; 204). Another study estimates a relatively high rate of thromboembolic events, including strokes, in up to 25% of patients, which appears to be a dose-independent side effect (169).
Gemcitabine. This is a deoxycytidine analogue used for the treatment of pancreatic cancer, but it also has activity against other tumors, including breast cancer and small cell lung cancer. Neurotoxicity is uncommon, but up to 10% of patients experience mild paresthesias, and, rarely, more severe peripheral and autonomic neuropathies (66). Administration of gemcitabine after radiation therapy for brain metastases may increase the risk of neurotoxicity (131).
Hydroxyurea. This is an antimetabolite used to treat chronic myelogenous leukemia and certain solid tumors, including melanoma, ovarian carcinoma, trophoblastic neoplasms, and meningiomas as well as cervical, head and neck, and prostate cancers. Rarely, it causes headaches, drowsiness, hallucinations, confusion, and seizures (53).
Irinotecan. This is a topoisomerase inhibitor used to treat cancer of the colon, lung, and skin. It also has been used in combination with bevacizumab in patients with malignant glioma. Severe neurologic toxicity has not been observed, but some patients experience transient visual disturbances and symptoms suggestive of cholinergic overactivity (204). In combination with other chemotherapeutic agents, such as 5-fluorouracil, neurotoxicity has been reported and may present in these patients as posterior reversible leukoencephalopathy (05; 101; 203).
Levamisole. Levamisole is an immune-enhancer that is used in combination with 5-fluorouracil for patients with colon cancer. A metabolite, p-hydroxy-tetramisole, may enhance 5-fluorouracil activity by inhibiting tyrosine phosphatase. When used in combination with 5-fluorouracil, it can cause a multifocal leukoencephalopathy (120; 142; 246). Rarely, levamisole may cause headache, insomnia, dizziness, seizures, or aseptic meningitis when used as a single agent.
Mechlorethamine (nitrogen mustard). This alkylating agent is used to treat Hodgkin lymphoma and malignant pleural effusions. Rarely, it causes somnolence, headaches, vertigo, hearing loss, and weakness. When used at high doses for bone marrow transplantation, confusion may occur (53).
Mitomycin C. This is an alkylating agent used to treat carcinomas of the gastrointestinal tract, breast cancer, and head and neck malignancies. It has been associated with an encephalopathy caused by thrombotic microangiopathy (65).
Nelarabine. Nelarabine is a cytotoxic deoxyguanosine analogue prodrug approved for treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Neurologic complications were observed in 76% of adult subjects treated on phase I and II clinical trials (189). Most were mild to moderate (grade 1 to 2), including headache, somnolence, neuropathy, and sensory deficits. However, grade 3, grade 4, and grade 5 (fatal) neurologic events were observed in 19% of patients, including cranial neuropathies (oculomotor and abducens nerve palsies), progressive multifocal leukoencephalopathy, peripheral demyelination similar to Guillain-Barré syndrome, cerebral and intracranial hemorrhage, coma, status epilepticus, demyelination, and metabolic encephalopathy (147; 228; 189). The median time to onset of the first neurologic event was 5 days from first infusion (189). Because of these uncommon but severe toxicities, the prescribing information insert on nelarabine contains a black box warning recommending discontinuation for grade 2 or higher neurologic adverse reaction (189).
Pentostatin. This adenosine deaminase inhibitor is used for the treatment of a variety of leukemias, including hairy cell leukemia. At low doses, lethargy is a common neurotoxic side effect, whereas higher doses can cause encephalopathy, seizures, and coma (43; 204).
Retinoic acid. All-transretinoic acid and 13-cis-retinoic acid are vitamin A derivatives that are so-called differentiation agents with activity against several solid tumors and hematologic malignancies. It has mostly been used to treat promyelocytic leukemia. Retinoic acid frequently causes headaches (11). Rarely, it can cause pseudotumor cerebri (252) and multiple mononeuropathies (300). It may also be associated with depression and increased risk of suicide.
Temozolomide. This oral alkylating agent plays a central role in the treatment of gliomas and melanoma and has been investigated for treatment of numerous other malignancies. Approximately 40% of patients receiving the drug experience headaches, although serious neurologic complications are rare (301). It is possible that these headaches are primarily due to the primary disease being treated (glioma) and less likely due to the temozolomide.
Teniposide. This is a topoisomerase inhibitor used for acute lymphoblastic leukemia, Kaposi sarcoma, and cutaneous T-cell lymphoma. It has rarely been associated with paresthesias, fatigue, somnolence, and seizures. It can, however, enhance vincristine-induced neuropathy when used in combination (273; 126).
Thioguanine. This purine antimetabolite is used to treat leukemia and brain tumors. Rarely, it causes loss of vibratory sense, encephalopathy, and ataxia, likely secondary to hepatic toxicity.
Thiotepa. This is an alkylating agent occasionally used to treat leptomeningeal metastases. Rarely, intrathecal thiotepa causes a myelopathy (103). High intravenous doses of thiotepa can produce encephalopathy that can be fatal (261; 204).
Topotecan. This is a topoisomerase inhibitor mostly used in the treatment of ovarian cancer. It can occasionally cause headaches and paresthesias (29).
Hormonal therapy
Aromatase inhibitors (anastrozole, exemestane, and letrozole). These selective aromatase inhibitors are used in the treatment in postmenopausal women with hormone receptor-positive breast cancer. Headaches occur in about 10% of patients treated with aromatase inhibitors. Anastrozole is also uncommonly associated with carpal tunnel syndrome, with most cases reported as mild to moderate in intensity and occurring within 18 months of treatment initiation (253).
Corticosteroids. Corticosteroids are frequently used in cancer patients for a variety of reasons. They reduce peritumoral edema in patients with primary and secondary brain tumors and spinal cord edema in patients with epidural spinal cord compression. Corticosteroids have a direct cytotoxic effect against neoplastic lymphocytes and are used in the treatment of leukemias and lymphomas. High-dose corticosteroids are frequently given with chemotherapy to reduce nausea and vomiting, whereas low doses are used to improve appetite and sense of well-being in some cancer patients.
The side effects of prolonged steroid therapy are well known (281; 62). The incidence of complications increases with higher doses and prolonged therapy, but individual susceptibility varies significantly.
Systemic side effects include a cushingoid appearance, truncal obesity, hirsutism, acne, impaired wound healing, striae, easy bruising and capillary fragility, immunosuppression, hypertension, glucose intolerance, electrolyte disturbance, fluid retention, peripheral edema, increased appetite, gastrointestinal bleeding, osteoporosis, avascular necrosis, growth retardation, cataracts, glaucoma, and visual blurring.
The neurologic complications of corticosteroids are summarized in Table 2.
Table 2. Neurologic Complications of Corticosteroids
|
Common |
Uncommon |
|
Myopathy |
Psychosis |
The most common complication is steroid myopathy (67; 71). Steroid-induced myopathy is classically characterized by weakness of the proximal muscles affecting primarily the hip girdle. Patients typically complain of difficulty getting up from a chair or climbing stairs. In severe cases, the pectoral girdle and neck muscles may also be involved. Steroid myopathy tends to occur after prolonged use of high doses of steroids, but there is significant variation in patient susceptibility, and some patients develop a myopathy after using low doses of steroids for only a short period. Creatine kinase levels are usually not elevated.
Corticosteroids often produce alterations in mood. An improved sense of well-being, anxiety, irritability, insomnia, difficulty concentrating, and depression are all relatively common. Occasionally, patients may develop steroid psychosis. This usually takes the form of acute delirium, but the psychosis may resemble mania, depression, or schizophrenia.
Other common neurologic complications of corticosteroids include tremors, visual blurring, reduced sense of taste and smell, and cerebral atrophy on neuroimaging studies. Rare complications include hiccups, dementia, seizures, and cord compression resulting from epidural lipomatosis (205).
Steroid withdrawal can also produce a variety of symptoms, which can be quite disabling. These include headaches, lethargy, nausea, vomiting, anorexia, myalgia and arthralgia (pseudo-rheumatism), fever, abdominal pain, postural hypotension, pseudotumor, and panniculitis.
Enzalutamide. Enzalutamide is an androgen receptor inhibitor used to treat metastatic castration-resistant prostate cancer. Clinical trials reported seizures in as many as 2% of patients treated with enzalutamide at doses greater than 360 mg/day and less than 1% at a dose of 160 mg/day (259). In a prospective, international, multicenter, post-approval study of 366 patients treated with enzalutamide 160 mg/day with at least one known risk factor for seizure at baseline (including use of a concomitant medication that lowered the seizure threshold, history of brain injury, or history of stroke or TIA), 1.1% had at least one confirmed seizure within 4 months of enzalutamide initiation (259).
Goserelin. This is an analogue of luteinizing hormone-releasing hormone used to treat prostate and breast cancer. When the drug is first used it can produce a tumor flare, resulting in bone pain and potentially exacerbating cord compression.
Leuprolide acetate. This is a gonadotropin-releasing hormone analogue used to treat prostate cancer and refractory breast cancer. Neurologic complications are uncommon, but it can cause headaches, dizziness, and paresthesias.
Mitotane (OP'-DDD). This drug, which suppresses adrenocorticosteroid production and is cytotoxic to adrenal cortical cells, is used to treat adrenocortical carcinoma. It produces lethargy, sedation, and dizziness in 40% of patients (152).
Octreotide. This is a long-acting analogue of somatostatin used to treat carcinoid tumors, vasoactive intestinal peptide-secreting tumors, and certain pituitary adenomas. It can cause headaches, dizziness, and rarely seizures.
Tamoxifen. This is a selective estrogen receptor modulator antiestrogen used to treat estrogen receptor-positive breast cancer. It can produce retinopathy, encephalopathy, and ataxia, especially when used in high doses (53). Tamoxifen-related toxicities include irritability, confusion, and ocular toxicities (16). Cognitive adverse effects have been reported and may be often unrecognized (250; 08; 01).
Toremifene citrate. Toremifene citrate is an antiestrogen used to treat breast cancer. Neurologic complications are uncommon, but patients may experience dizziness, depression, tremor, blurred vision, and ataxia (89).
Biological response modifiers
Alpha interferon. This agent is occasionally used in hairy cell leukemia, Kaposi sarcoma, melanoma, and myeloma. Systemic toxicities include flu-like symptoms and myelosuppression. Flu-like symptoms tend to be worse at the onset of therapy and usually improve with time. Neurotoxicity tends to be dose dependent. It is generally mild when low doses of alpha-interferon are used as adjuvant therapy in patients with malignant melanoma (36). At higher doses, alpha-interferon can cause headaches, confusion, lethargy, hallucinations, and seizures (231; 179; 180). These are usually reversible, but occasionally a permanent dementia or a persistent vegetative state may result (179; 180). Rarely, alpha interferon has been associated with oculomotor palsy, sensorimotor neuropathy (239), myasthenia gravis (25), brachial plexopathy, and polyradiculopathy (54).
A high incidence of neuropsychiatric toxicity has been noted in patients treated with recombinant interferon alpha-2b. In a study of 91 patients with chronic myelogenous leukemia, one quarter experienced grade 3 or 4 neuropsychiatric toxicity that affected daily functioning. All patients recovered on withdrawal of interferon alpha-2b. Patients with a psychiatric history were more likely to develop severe neuropsychiatric toxicity than patients without a psychiatric history (112).
Interleukin-2 (IL-2). IL-2 has been used alone and in combination with lymphokine-activated killer cells and tumor-infiltrating lymphocytes in the treatment of various cancers, especially renal cell carcinoma and melanoma. Neuropsychiatric complications occur in approximately 30% to 50% of patients (55). These include cognitive changes, delusions, hallucinations, and depression. In addition, there have been reports of transient focal neurologic deficits (17), acute leukoencephalopathy, carpal tunnel syndrome, and brachial neuritis (162). Administration of IL-2 directly into the tumor bed for the treatment of gliomas can cause significant cerebral edema (14).
One case of severe neurotoxicity has been reported in a patient treated with IL-2 in combination with granulocyte-macrophage-colony stimulating factor. This patient experienced a fatal cerebral hemorrhage associated with thrombocytopenia, leading the authors to recommend extreme caution when using these agents together (122).
Growth factors
Colony-stimulating factors (granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor). Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor are used to increase the granulocyte and neutrophil cell counts and reduce the incidence of infections in patients with non-myeloid tumors receiving chemotherapy. Musculoskeletal symptoms such as cramps and bone pain commonly occur. Rarely, they cause fatigue and headaches. Other very rare adverse reactions with higher dose applications include confusion (227) and reversible posterior leukoencephalopathy (157).
Erythropoietin. This is used to stimulate red blood cell production. Some patients may experience fatigue, dizziness, and paresthesias, but serious neurologic complications have not been described. With long-term administration, erythropoietin has rarely been associated with hypertensive encephalopathy and seizures.
Oprelvekin. This is a recombinant platelet growth factor used to prevent severe chemotherapy-induced thrombocytopenia and for platelet transfusion following myelosuppressive chemotherapy. Neurologic complications are uncommon, but some patients complain of headaches, dizziness, insomnia, and paresthesias.
Monoclonal antibodies
Bevacizumab. This is a monoclonal antibody directed against vascular endothelial growth factor. It is used in patients with colorectal, breast, non-small cell lung cancer, and malignant glioma. There have been reports of syncope, hypertension, cerebral thrombosis and hemorrhage, and reversible posterior leukoencephalopathy (94; 201; 61; 234; 272). Rarely, severe optic neuropathy has been reported in patients with brain tumors after bevacizumab treatment (257). Patients with brain metastases were often excluded from clinical trials of VEGF/VEGFR inhibitors due to the concern for intratumoral hemorrhage. However, subsequent studies of anti-VEGF therapy found relatively low rates of intracranial hemorrhage, even in the presence of CNS metastases (37; 232). The incidence of arterial thromboembolic events including strokes is slightly elevated in patients treated with bevacizumab (42). Approximately 2% to 3% of patients with glioblastoma treated with bevacizumab will have an ischemic stroke (81; 251).
Blinatumomab. This is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, and minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. In a phase 2 clinical trial of 189 patients with Ph- ALL (264), 52% of patients experienced a neurologic adverse event, such as dizziness, tremor, confusion, or encephalopathy. Most neurologic events occurred during the first cycle, were mild in severity, and resolved with treatment interruption and after use of dexamethasone.
Brentuximab vedotin. This is an antibody-drug conjugate targeting CD30 and is commonly used in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Peripheral neuropathy (24% any grade, 6% grade 3 or 4) is the most frequent nonhematologic adverse event reported, sometimes requiring treatment discontinuation (305). Rarely, progressive multifocal leukoencephalopathy has been reported in patients who received brentuximab vendotin (38).
Cetuximab. This chimeric mouse-human antibody targeted against epidermal growth factor is FDA approved for head and neck cancer as well as colorectal cancer. Cases of aseptic meningitis (76) and chronic immune-mediated demyelinating polyneuropathy (18) have been reported in association with cetuximab. Patients may also develop decrease in magnesium levels, causing severe fatigue, cramps, and somnolence (270).
Gemtuzumab ozogamicin. Gemtuzumab ozogamicin is an antibody targeted chemotherapeutic agent used in patients with CD33+ acute myelogenous leukemia. It can cause headaches and dizziness. Severe thrombocytopenia is common and may result in intracranial hemorrhage.
Ibritumomab tiuxetan. This is a radiopharmaceutical that is used for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma. It is a combination of monoclonal antibody ibritumomab bound to tiuxetan (chelated to Y-90 and In-111) and directed against the CD20 antigen on lymphoma cells. Neurologic side effects include headaches (12%), dizziness (10%), back pain (8%), insomnia (5%), and encephalopathy (less than 1%) (298).
Iodine-131 tositumomab. This is a radiolabeled immunoglobulin G-2a murine monoclonal antibody directed against the CD20 antigen. In addition to the cytotoxic effects induced by the antibody, the presence of iodine-131 results in focused targeting of beta radiation to the tumor and surrounding tissue. To date, it has been primarily used to treat relapsed or refractory non-Hodgkin lymphoma. Iodine-131 tositumomab is well-tolerated. A minority of patients experience headache or myalgia, and a few develop hypothyroidism (133; 284).
Rituximab. Rituximab is a genetically engineered chimeric murine and human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. It is used for the treatment of low-grade or follicular B-cell lymphoma. Neurologic complications are uncommon, but some patients complain of headaches, myalgia, dizziness (173), or paresthesias (79). There may be an increased risk for patients treated with rituximab to develop progressive multifocal leukoencephalopathy, with a reported incidence of 1 per 32,000 in HIV-negative patients (23).
Trastuzumab and ado-trastuzumab emtansine. Trastuzumab is a humanized anti-p185(HER2) monoclonal antibody used alone or in combination with chemotherapeutic agents in patients with HER/neu-overexpressing metastatic breast cancer (254). Rarely, patients will experience headaches, dizziness, and insomnia after infusion of the antibody (46).
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate containing trastuzumab and the microtubule inhibitor DM1 and is also used in the treatment of advanced HER/neu-overexpressing breast cancer. In a randomized clinical trial, 2% of patients in the T-DM1 group experienced grade 3 peripheral neuropathy compared to 0.2% in the lapatinib plus capecitabine group (57). T-DM1 may increase the risk of clinically significant radiation necrosis and cerebral edema in brain metastases treated with stereotactic radiosurgery (266), although further data are needed from ongoing clinical trials of T-DM1 to support these findings.
Targeted molecular agents
Bortezomib. This is a proteosome inhibitor frequently used in the treatment of patients with multiple myeloma. A subacute sensory, and often painful, axonal neuropathy occurs in approximately 35% of patients and results in dose reduction in 12% (223). Autonomic dysfunction may occur, but motor fibers are rarely affected (132). The risk of bortezomib-induced peripheral neuropathy is increased in patients with a preexisting neuropathy. Nerve conduction studies may be normal, as small fibers are preferentially affected. Treatment discontinuation or dose modification leads to improvement in most patients (223; 224). A dose adjusted algorithm is available for patients who develop bortezomib-related neuropathy (www.accessdata.fda.gov/drugsatfda_docs/label/2008/021602s015lbl.pdf).
Ibrutinib. Ibrutinib is a first-in-class oral irreversible inhibitor of Bruton tyrosine kinase (BTK) used in the treatment of a variety of B cell malignancies including mantel cell lymphoma, chronic lymphocytic leukemia, and Waldenström macroglobulinemia. Although direct neurologic toxicities are uncommon, ibrutinib and other newer generation Bruton tyrosine kinase inhibitors can increase the risk of invasive fungal infections, including CNS aspergillosis (41; 156; 22).
Imatinib mesylate. Imatinib is a protein tyrosine kinase inhibitor of the BCR-Abl oncogene and c-kit used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. Neurologic side effects are usually mild and may include headache and fatigue (48). Rarely, cerebral edema and encephalopathy may occur.
Ivosidenib. This inhibitor of isocitrate dehydrogenase 1 (IDH1) is approved for use in adults with acute myeloid leukemia (AML). Based on a safety assessment of 258 patients treated with ivosidenib, two patients (less than 1%) developed Guillain-Barre syndrome (129).
Larotrectinib. This oral TRK inhibitor is used in the treatment of adult and pediatric solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion, a rare driver of cancers. Among 176 patients treated with larotrectinib on trial, 53% experienced neurologic adverse reactions of any grade, including 6% grade 3 and 0.6% grade 4 (154; 168). The most common neurologic toxicities included delirium, dysarthria, dizziness, gait disturbance, and paresthesias.
Lorlatinib. Lorlatinib is an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 with good blood-brain barrier penetration and is used in the treatment of ALK-positive metastatic non-small cell lung cancer. Peripheral neuropathy was reported in 47% of patients, but most cases were mild and reversible with dose modifications or standard medical therapy (165; 15). In clinical trials, a variety of CNS toxicities occurred in 54% of patients receiving lorlatinib, including changes in cognitive function, mood, and speech (165; 15). Of those patients who experienced such CNS side effects, 71.8% had CNS metastases at baseline. Most toxicities were mild, intermittent, and improved or resolved with dose modifications.
Sorafenib. This is a multikinase inhibitor, with activity against CRAF, BRAF and mutant BRAF receptors, and extracellular KIT, FLT-3, VEGFR-2, VEGFR-3 and PDGFR-B receptors. It has been approved for renal cancer, hepatocellular carcinoma, and thyroid cancer. Rarely has it been associated with peripheral neuropathies. Sorafenib is associated with a slightly increased incidence of arterial thromboembolic events including strokes (42), similar to what has been described with the use of bevacizumab.
Sunitinib. This molecularly targeted agent inhibits multiple tyrosine receptor kinases, including PDGFR, KIT, and VEGFR. It is approved for advanced renal cancer and gastrointestinal stromal tumor. Sunitinib has been reported to induce reversible cognitive disorder characterized by confusion, hallucinations, and extrapyramidal symptoms (249).
Tipifarnib. This is a methyl-quinolone, which is a selective inhibitor of farnesyl transferase. It is currently being evaluated in phase II and III trials in a variety of cancers. It can cause a peripheral neuropathy. CNS complications are uncommon, but some patients experience lethargy, confusion, ataxia, photophobia, and neuropathy (134; 220).
Immunotherapy
Chimeric antigen receptor (CAR) T cell therapy. In CAR T cell therapy, a patient’s own T lymphocytes are genetically modified ex vivo to attack specific proteins, expanded in a production facility, and infused back into the patient (30). Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy approved for the treatment pediatric B-cell precursor acute lymphoblastic leukemia (ALL), whereas axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy approved for use in relapsed or refractory diffuse large B cell lymphoma. Several other CAR-T cell therapies are currently being evaluated in clinical trials, including for hematological malignancies and solid cancers. By the beginning of 2024, six CAR-T cell products targeting either CD19 or BCMA were FDA approved (Axicabtagene ciloleucel, Tisagenlecleucel, Brexucabtagene autoleucel, Ciltacabtagene autoleucel, Idecabtagene vicleucel and Lisocabtagene maraleucel).
A cytokine release syndrome (CRS) is the most common toxicity associated with CAR T cell therapies, which is characterized by a systemic inflammatory response and can lead to widespread reversible organ dysfunction. Treatment includes aggressive supportive care, including management of hypotension and any concurrent infections, as well as consideration of interleukin-6 receptor blockade with tocilizumab (30; 176; 31).
Neurologic toxicities have been reported with anti-CD19 CAR T cells at high frequency in up to 80% of patients and with varying manifestations, including headache, confusion, somnolence, hallucinations, dysphasia, ataxia, apraxia, facial nerve palsy, tremor, dysmetria, and seizures (102; 244; 30; 136; 58). Deaths related to cerebral edema have been reported in a small number of patients. Neurotoxicity mostly occurs in the setting of cytokine release syndrome (176). The manifestations can be severe, sometimes necessitating intubation and ventilation for airway protection, and ICU management.
Noteworthy, the frequency of immune effector cell-associated neurotoxicity syndrome (ICANS) in patients treated for CNS lymphoma appears less common than following treatment for systemic lymphoma, and emerging data suggest that neurotoxicity is usually mild and occurs in approximately 40% to 50% of CNS lymphoma patients treated with CAR-T cells (50; 137).
The etiology of ICANS is poorly understood but thought to be driven by endothelial cell injury and disruption of the blood brain barrier (303).
In patients treated with CAR-T cells for CNS malignancies, a distinct syndrome of “tumor inflammation-associated neurotoxicity” (TIAN) may occur and can be life-threatening, resulting from increased intracranial pressure and brain herniation (172).
An emerging syndrome of parkinsonism has been described in patients treated with BCMA targeted CAR-T cell therapy for multiple myeloma and appears to occur with delayed onset by 1 to 2 months in approximately 2% to 3% of patients (279; 135).
This syndrome has been termed “movement and neurocognitive treatment-emergent adverse events” (MNT) and may occur in combination with personality and behavioral changes, or cranial and peripheral neuropathies (47).
Retrospective reviews suggest increased risk of neurotoxicity in young patients, higher tumor burden, presence of high levels of CD19+ cells in the bone marrow, high CAR-T cell dose, pre-existing neurologic comorbidity, higher peak CAR-T cell expansion, and early and higher elevations of proinflammatory cytokines in blood (102; 244; 136; 86). Limited experience suggests that tocilizumab may not ameliorate neurologic toxicity. Instead, supportive care, symptomatic management (such as with antiseizure medications), and corticosteroids are recommended for severe neurologic toxicities (188; 176; 170).
Ipilimumab. Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that inhibits the immune system, and is approved for use in unresectable or metastatic melanoma. The incidence of neurologic complications is low, less than 4% with ipilimumab alone and 12% with combination ipilimumab and anti-PD1 therapy (218). Common neurologic symptoms include headache, although most cases are mild (121). Immune-related neurologic complications have rarely been described, including inflammatory myopathy (123), aseptic meningitis, posterior reversible encephalopathy syndrome (269), Guillain-Barre syndrome (292), inflammatory enteric neuropathy (19), a myasthenia gravis-like syndrome, chronic inflammatory demyelinating polyneuropathy, transverse myelitis (158), and a meningo-radiculo-neuritis (121). Autoimmune encephalitis has also been reported in patients treated with combined ipilimumab and nivolumab (293). Immunotherapy-related neurologic complications are a diagnosis of exclusion (297). Therefore, diagnostic evaluation is often aimed at ruling out other causes (such as hypophysitis, infectious etiologies, metastatic disease, strokes, seizures, paraneoplastic disorders, and toxic-metabolic derangements) (153; 100). Management of neurologic toxicities involves prompt recognition and intervention. For moderate to severe toxicities, cessation of immunotherapy and corticosteroids may be indicated (153; 218). The National Comprehensive Cancer Network (NCCN) provides guidelines for management of immunotherapy-related toxicities (187).
PD-1 inhibitors (cemiplimab, nivolumab, and pembrolizumab) and PD-L1 inhibitors (atezolizumab, avelumab, and durvalumab). Cemiplimab, nivolumab, and pembrolizumab are programmed death 1 (PD-1) immune checkpoint inhibitor antibodies, whereas atezolizumab, avelumab and durvalumab are anti-programmed death ligand 1 (PD-L-1) antibodies. These agents are collectively approved for use in non-small cell lung cancer, head and neck cancer, colorectal cancer, urothelial cancer, hepatocellular carcinoma, and melanoma. The incidence of neurologic complications is low, 6% with anti-PD1 therapy alone and 12% with combination ipilimumab and anti-PD1 therapy (218). Neurologic complications similar to ipilimumab have been described with anti-PD1 therapy, including cases of Guillain-Barre syndrome, myasthenia gravis, facial and abducens nerve paresis, demyelination, and acute encephalitis (121; 139; 153; 297; 238). Also similar to ipilimumab, management of neurologic toxicities may include diagnostic evaluation for other causes, cessation of immunotherapy, or corticosteroids (153; 218). The NCCN provides guidelines for management of immunotherapy-related toxicities (187).
Other agents
Amifostine. This is a thiophosphate cytoprotectant agent that is used to reduce renal toxicity associated with cisplatin. There is also evidence that it may reduce the neurotoxicity of many chemotherapeutic agents, including cisplatin (64), carboplatin, and paclitaxel (166), but there are conflicting reports (197). Neurologic complications are uncommon but amifostine may cause hypotension and lead to syncope. There have been rare reports of seizures.
Bisphosphonates: pamidronate and zoledronic acid. These are used to treat hypercalcemia and bony metastases. Approximately 2% of patients experience insomnia, sleepiness, or abnormal vision.
Denileukin diftitox. Denileukin diftitox is a fusion toxin used to treat cutaneous T-cell lymphoma expressing the CD25 component for the IL-2 receptor. The most common complication is a vascular leak syndrome, but some patients experience myalgias, dizziness, paresthesias, nervousness, confusion, and insomnia (196; 06).
References
- 01
- Abdallah IB, Rachdi H, Mejri N et al. Cognitive complaints during breast cancer endocrine therapy: aromatase inhibitors versus tamoxifen. BMJ Support Palliat Care 2022:bmjspcare-2021-003377. PMID 35383047
- 02
- Aeschlimann C, Cerny T, Kupfer A. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 1996;24:1336-9. PMID 8971139
- 03
- Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007;19:108-14. PMID 17355105
- 04
- Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014;3:CD005228. PMID 24687190
- 05
- Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475-8. PMID 17030665
- 06
- Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3(3):193-215. PMID 11978140
- 07
- Aplin CG, Russell-Jones R. Acute dysarthria induced by low dose methotrexate therapy in a patient with erythrodermic cutaneous T-cell lymphoma: an unusual manifestation of neurotoxicity. Clin Exp Dermatol 1999;24(1):23-4. PMID 10233644
- 08
- Apple AC, Schroeder MP, Ryals AJ, et al. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. Neuroimage Clin 2018;20:110-8. PMID 30094161
- 09
- Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218-28. PMID 18329278
- 10
- Baehring JM, Fulbright RK. Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 2008;79:535-9. PMID 17682013
- 11
- Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995;13(8):1966-74. PMID 7636537
- 12
- Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991;9:679-93. PMID 1648599
- 13
- Balin J, Parmar H, Kujawski L. Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity. J Neurol Sci 2008;269:169-71. PMID 18191947
- 14
- Barba D, Saris S, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175-82. PMID 2643685
- 15
- Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist 2019;24(8):1103-10. PMID 30890623
- 16
- Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 2001;21(5):407-24. PMID 11369162
- 17
- Bernard JT, Ameriso S, Kempf RA, et al. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990;40:154-5. PMID 2296362
- 18
- Beydoun SR, Shatzmiller RA. Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment. Clin Neurol Neurosurg 2010;112(10):900-2. PMID 20685033
- 19
- Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009;32(2):203-5. PMID 19238020
- 20
- Black FO, Myers EN, Schramm VL, et al. Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope 1982;92(12):1363-8. PMID 6983636
- 21
- Blaes AH, Santa-Cruz KS, Lee CK, Hui SK, Peterson BA. Necrotizing leukoencephalopathy following CHOP chemotherapy. Leuk Res 2008;32:1611-4. PMID 18378307
- 22
- Blaize M, Thizy G, Boissonnas A, et al. Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib: findings from three cases. Int J Infect Dis 2024;142:107000. PMID 38461932
- 23
- Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control 2017;24(4):1073274817729901. PMID 28975841
- 24
- Boogerd W, vd Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988;51(10):1277-83. PMID 3225584
- 25
- Bora I, Karli N, Bakar M, Zarifoglu M, Turan F, Ogul E. Myasthenia gravis following IFN-alpha-2a treatment. Eur Neurol 1997;38:68. PMID 9252802
- 26
- Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol 1997;34(2):163-7. PMID 9210064
- 27
- Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008;8:7. PMID 18796166
- 28
- Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009:1-10. PMID 19308757
- 29
- Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, et al. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gyn Onc 2000;79(3):495-8. PMID 11104627
- 30
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019;34:45-55. PMID 30528964 30528964
- 31
- Brudno JN, Kochenderfer JN. Current understanding and management of CAR-T cell-associated toxicities. Nat Rev Clin Oncol 2024;21(7):501-21. PMID 38769449
- 32
- Brugnoletti F, Morris EB, Laningham FH, et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer 2009;52:293-5. PMID 18831032
- 33
- Brunello A, Basso U, Rossi E, et al. Ifosfamide-related encephalopathy in elderly patients: report of five cases and review of the literature. Drugs Aging 2007;24:967-73. PMID 17953463
- 34
- Budde LS, Hanna NH. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma. Expert Rev Anticancer Ther 2004;4:361-8. PMID 15161435
- 35
- Cain MS, Burton GV, Holcombe RF. Fatal leukoencephalopathy in a patient with non-Hodgkin's lymphoma treated with CHOP chemotherapy and high-dose steroids. Am J Med Sci 1998;315:202-7. PMID 9519935
- 36
- Caraceni A, Gangeri L, Martini C, et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 1998;83:482-9. PMID 9690541
- 37
- Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy. Neuro Oncol 2008;10(4):624-30. PMID 18539884
- 38
- Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014;120(16):2464-71. PMID 24771533
- 39
- Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004;62(12):2291-3. PMID 15210898
- 40
- Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven, 1996.
- 41
- Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis 2018;66(1):140-8. PMID 29029010
- 42
- Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6(8):465-77. PMID 19581909
- 43
- Cheson BD, Vena DA, Foss FM, et al. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994;12:2216-28. PMID 7931492
- 44
- Ch'ien LT, Aur RJ, Verzosa MS, et al. Progression of methotrexate-induced leukoencephalopathy in children with leukemia. Med Pediatr Oncol 1981;9(2):133-41. PMID 6939956
- 45
- Choi BS, Robins HI. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine. Cancer Chemother Pharmacol 2008;61:345-6. PMID 18026678
- 46
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-48. PMID 10561337
- 47
- Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12(2):32. PMID 35210399
- 48
- Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-42. PMID 12006504
- 49
- Collins MP, Amato AA. Peripheral nervous system diseases associated with malignancy. In: Brown WF, Bolton CF, Aminoff MJ, editors. Neuromuscular function and disease. Basic, clinical, and electrodiagnostic aspect. Orlando: W.B. Saunders Company, 2002:1185-220.
- 50
- Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR-T cell therapies in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv 2023;7(1):32-9. PMID 36260734
- 51
- Courtney MJ, Coffey ET. The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci 1999;11(3):1073-84. PMID 10103100
- 52
- David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005;28(3):277-80. PMID 15923801
- 53
- DeAngelis LM, Posner JB. Side effects of chemotherapy. In: DeAngelis LM, Posner JB, editors. Neurologic complications of cancer. 2nd ed. New York: Oxford University Press, 2009:447-510.
- 54
- Delattre JY, Vega F, Chen Q. Neurologic complications of immunotherapy. In: Wiley RG, editor. Neurologic complications of cancer. New York: Marcel Dekker, 1995:267-93.
- 55
- Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300. PMID 3497595
- 56
- Di Cataldo A, Astuto M, Rizzo G, Bertuna G, Russo G, Incorpora G. Neurotoxicity during ifosfamide treatment in children. Med Sci Monit 2009;15:CS22-25. PMID 19114973
- 57
- Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18(6):732-42. PMID 28526536
- 58
- Dietrich J. Neurotoxicity of cancer therapies. Continuum (Minneap Minn) 2020;26(6):1646-72. PMID 33273176
- 59
- Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5(7):22. PMID 17125495
- 60
- Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004;38(2):242-6. PMID 14742759
- 61
- Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol 2008;21:736-44. PMID 19060566
- 62
- Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 2011;4(2):233-42. PMID 21666852
- 63
- Dietrich J, Wen P. Neurologic complications of chemotherapy. In: Schiff D, Kesari S, Wen P, editors. Cancer Neurology in Clinical Practice. Totowa, New Jersey: Humana Press Inc, 2008:287-326.
- 64
- DiPaola RS, Schuchter L. Neurologic protection by amifostine. Semin Oncol 1999;26:82-8. PMID 10348265
- 65
- Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992;19:580-96. PMID 1411655
- 66
- Dormann AJ, Grunewald T, Wigginghaus B, Huchzermeyer H. Gemcitabine-associated autonomic neuropathy. Lancet 1998;351:644. PMID 9500323
- 67
- Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41:1235-9. PMID 1866012
- 68
- Duffner PK. The long term effects of chemotherapy on the central nervous system. J Biol 2006;5(7):21. PMID 17140427
- 69
- Dunton SF, Nitschke R, Spruce WE, Bodensteiner J, Krous HF. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study. Cancer 1986;57(6):1083-8. PMID 3455842
- 70
- Dworkin LA, Goldman RD, Zivin LS, Fuchs PC. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol 1985;3(5):613-6. PMID 3998779
- 71
- Eidelberg D. Steroid myopathy. In: Rottenberg DA, editor. Neurological complications of cancer treatment. Boston: Butterworth-Heinemann, 1991:185-91.
- 72
- Erbetta A, Salmaggi A, Sghirlanzoni A, et al. Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. Neurol Sci 2008;29:131-7. PMID 18612759
- 73
- Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25:13-22. PMID 9609104
- 74
- Fazeny B, Zifko U, Meryn S, et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel-a phase II study. Cancer Chemother Pharmacol 1996;39:150-6. PMID 8995513
- 75
- Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988;38:127-33. PMID 3275903
- 76
- Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol 2009;20(9):1609-10. PMID 19643807
- 77
- Fisher MJ, Khademian ZP, Simon EM, Zimmerman RA, Bilaniuk LT. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 2005;26(7):1686-9. PMID 16091514
- 78
- Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997;17(5 pt 2):146S-154S. PMID 9322882
- 79
- Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18(2):317-24. PMID 10637245
- 80
- Forsyth PA, Cascino TL. Neurologic complications of chemotherapy. In: Wiley RG, editor. Neurologic complications of cancer. New York: Marcel Dekker, 1995:241-66.
- 81
- Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 2011;105(2):281-9. PMID 21603965
- 82
- Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996;47:115-8. PMID 8710063
- 83
- Frustaci S, Barzan L, Comoretto R, Tumolo S, Lo Re G, Monfardini S. Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. Cancer Treat Rep 1987;71(3):257-9. PMID 3815392
- 84
- Gagliano RG, Costanzi JJ. Paraplegia following intrathecal methotrexate. Cancer 1976;37:1663-8. PMID 946593
- 85
- Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10(12 Pt 1):4055-61. PMID 15217938
- 86
- Genoud V, Migliorini D. Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Front Neurol 2023;14:1108297. PMID 36970518
- 87
- Gerl A, Clemm C, Schleuning M, Wilmanns W. Fatal cerebrovascular accident associated with chemotherapy for testicular cancer. Eur J Cancer 1993;29A:1220-1. PMID 7686022
- 88
- Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136-47. PMID 10623704
- 89
- Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006;106(3):505-13. PMID 16369994
- 90
- Gibson EM, Nagaraja S, Ocampo A, et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell 2019;176(1-2):43-55.e13. PMID 30528430
- 91
- Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355:1075-6. PMID 10744098
- 92
- Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999a;5:3394-402. PMID 10589750
- 93
- Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999b;17:3110-6. PMID 10506606
- 94
- Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354(9):980-2; discussion 980-2. PMID 16510760
- 95
- Gonzalez Castro LN, Dietrich J. Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neurooncol Pract 2020;8(3):259-65. PMID 34055373
- 96
- Gonzalez Perez P, Serrano-Pozo A, Franco-Macias E, Montes-Latorre E, Gomez-Aranda F, Campos T. Vincristine-induced acute neurotoxicity versus Guillain-Barre syndrome: a diagnostic dilemma. Eur J Neurol 2007;14:826-8. PMID 17594344
- 97
- Goodin S, Barbour S, Song J, Berrak E, Cox D. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer. Am J Health Syst Pharm 2015;72(24):2150-6. PMID 26637514
- 98
- Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55(10):1293-302. PMID 14499708
- 99
- Guglani S, Farrugia D, Elsdon M, Parmar M, Owen JR. Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel. Clin Oncol (R Coll Radiol) 2003;15(3):160-1. PMID 12801056
- 100
- Guidon AC, Burton LB, Chwalisz BK, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 2021;9(7):e002890. PMID 34281989
- 101
- Guiu S, Taillibert S, Chinot O, et al. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Rev Neurol (Paris) 2008;164:588-94. PMID 18565358
- 102
- Gust J, Hay KA, Hanafi LA, Li D, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7(12):1404-19. PMID 29025771
- 103
- Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thio-TEPA: a phase 2 study. Cancer Treat Rep 1977;61:885-7. PMID 408003
- 104
- Haefner MD, Siciliano RD, Widmer LA, Vogel Wigger BM, Frick S. Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie 2007;30(3):138-40. PMID 17341901
- 105
- Hall C, Dougherty WJ, Lebish IJ, Brock PG, Man A. Warning against use of intrathecal mitoxantrone. Lancet 1989;1(8640):734. PMID 2564552
- 106
- Hamdan MY, Frenkel EP, Bick R. L-asparaginase-provoked seizures as singular expression of central nervous toxicity. Clin Appl Thromb Hemost 2000;6(4):234-8. PMID 11030530
- 107
- Hammack JE, Cascino TL. Chemotherapy and other common drug-induced toxicities of the central nervous system in patients with cancer. In: Vecht CJ, editor. Handbook of clinical neurology. Amsterdam: Elsevier Science, 1998:481-514.
- 108
- Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008;7:12. PMID 18430259
- 109
- Haykin ME, Gorman M, van Hoff J, Fulbright RK, Baehring JM. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006;76(2):153-7. PMID 16411025
- 110
- Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998;64(5):667-9. PMID 9598687
- 111
- Henderson RD, Rajah T, Nicol AJ, Read SJ. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003;60(2):326-8. PMID 12552054
- 112
- Hensley ML, Peterson B, Silver RT, et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alpha-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000;18(6):1301-8. PMID 10715301
- 113
- Hertzberg H, Huk WJ, Ueberall MA, et al. CNS late effects after ALL therapy in childhood. Part I: neuroradiological findings in long-term survivors of childhood ALL--an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 1997;28(6):387-400. PMID 9143382
- 114
- Herzig RH, Hines JD, Herzig GP, et al. Cerebellar toxicity with high dose cytosine arabinoside. J Clin Oncol 1987;5:927-32. PMID 3585447
- 115
- Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Patten WL, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997;75:417-22. PMID 9020489
- 116
- Hilkens PH, van den Bent MJ. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 1997;2(4):350-61. PMID 10975744
- 117
- Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;25(25):4028-9. PMID 17664456
- 118
- Hochster HS, Grothey A, Shpilsky A, Childs BH. Effect of intravenous (IV) calcium and magnesium vs placebo on response to FOLFOX + bevacizumab in the CONcePT trial. Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 20, 2008.
- 119
- Hogan-Dann CM, Fellmeth WG, McGuire SA, et al. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984;252:2862-3. PMID 6092732
- 120
- Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31:262-7. PMID 1637134
- 121
- Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29(6):806-12. PMID 27653290
- 122
- Hotton KM, Khorsand M, Hank JA, et al. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases. Cancer 2000;88:1892-901. PMID 10760767
- 123
- Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009;36(4):518-20. PMID 19650371
- 124
- Hwang TL, Yung A, Estey EH, et al. Central nervous system toxicity with high dose Ara-C. Neurology 1985;35:1475-7. PMID 4033929
- 125
- Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993;72(2):587-93. PMID 8319192
- 126
- Ignoffo RJ, Viele CS, Damon LE, Venook A. Cancer chemotherapy pocket guide. Philadelphia: Lippincott-Raven, 1998.
- 127
- Ishii H, Oh H, Ishizuka N, et al. Cerebral infarction in a patient with acute lymphoblastic leukemia after fresh-frozen plasma replacement during L-asparaginase therapy. Am J Hematol 1992;41:295-6. PMID 1288293
- 128
- Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004;109(3):188-93. PMID 14763956
- 129
- Ivosidenib. TIBSOVO (R) tablets, ivosidenib tablets [package insert]. Cambridge, MA: Agios Pharmaceuticals Inc, 2018.
- 130
- Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109(8):3214-8. PMID 17209054
- 131
- Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400. PMID 12023144
- 132
- Jongen JL, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neurooncol 2015;121(2):229-37. PMID 25326770
- 133
- Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131(I) tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;15:1259-66. PMID 10942366
- 134
- Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-9. PMID 11369625
- 135
- Karschnia P, Arrillaga-Romany IC, Eichler A, et al. Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR-T cells. Neuro Oncol 2023a;25(12):2239-49. PMID 37402650
- 136
- Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 2019;133(20):2212-21. PMID 30808634
- 137
- Karschnia P, Miller KC, Yee AJ, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR-T cells. Blood 2023b;142(14):1243-8. PMID 37471607
- 138
- Khattab J, Terebelo HR, Dabas B. Phantom limb pain as a manifestation of paclitaxel neurotoxicity. Mayo Clin Proc 2000;75:740-2. PMID 10907391
- 139
- Khoja L, Maurice C, Chappell M, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016;4(3):175-8. PMID 26822024
- 140
- Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 2006;13(24):2901-7. PMID 17073636
- 141
- Kiewe P, Seyfert S, Korper S, Rieger K, Thiel E, Knauf W. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 2003;44(10):1815-8. PMID 14692540
- 142
- Kimmel DW, Schutt AJ. Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993;68(4):363-5. PMID 8455395
- 143
- Kocer B, Sucak G, Kuruoglu R, Aki Z, Haznedar R, Erdogmus NI. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. Acta Neurol Belg 2009;109(2):120-6. PMID 19681443
- 144
- Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32(1):51-60. PMID 15880395
- 145
- Kuker W, Bader P, Herrlinger U, Heckl S, Nagele T. Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. J Neurooncol 2005;73(1):47-9. PMID 15933817
- 146
- Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38(2):284-9. PMID 3340295
- 147
- Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005;23(15):3396-403. PMID 15908652
- 148
- Kut V, Patel JD, Argiris A. Pemetrexed: a novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther 2004;4(4):511-22. PMID 15270656
- 149
- Kwong YL, Yeung DY, Chan JC. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 2009;88:193-201. PMID 19050889
- 150
- La Morgia C, Mondini S, Guarino M, Bonifazi F, Cirignotta F. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci 2004;25(2):95-7. PMID 15221628
- 151
- Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25(16):2205-11. PMID 17470850
- 152
- Lanser JB, van Seters AP, Moolenaar AJ, Haak HR, Bollen EL. Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms. J Clin Oncol 1992;10(9):1504. PMID 1517795
- 153
- Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017;22(6):709-18. PMID 28495807
- 154
- Lassen UN, Albert CM, Kummar S, et al. Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach. Presented at: the ESMO 2018 Congress; Munich, Germany: October 19-23, 2018. Abstract 409O.
- 155
- Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25(2):137-45. PMID 10357081
- 156
- Lee EQ. Neurologic complications in patients with cancer. Continuum (Minneap Minn) 2020;26(6):1629-45. PMID 33273175
- 157
- Leniger T, Kastrup O, Diener HC. Reversible posterior leukoencephalopathy syndrome induced by granulocyte stimulating factor filgrastim. J Neurol Neurosurg Psychiatry 2000;69(2):280-1. PMID 10960294
- 158
- Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16(4):589-93. PMID 24482447
- 159
- Lindner LH, Ostermann H, Hiddemann W, et al. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol 2008;88:381-6. PMID 18836794
- 160
- Linnebank M, Pels H, Kleczar N, et al. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 2005;64(5):912-3. PMID 15753437
- 161
- Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-73. PMID 2564647
- 162
- Loh FL, Herskovitz S, Berger AR, Swerdlow ML. Brachial plexopathy associated with interleukin-2 therapy. Neurology 1992;42:462-3. PMID 1310533
- 163
- Loprinzi CL, Lacchetti C, Bleker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020;38(28):3325-48. PMID 32663120
- 164
- Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014;32(10):997-1005. PMID 24297951
- 165
- Lorlatinib. LORBRENA (R) tablets, lorlatinib tablets [package insert]. New York, NY: Pfizer Labs, 2018.
- 166
- Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003;14(7):1086-93. PMID 12853351
- 167
- Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther 2018;25(3):176-91. PMID 29789639
- 168
- Loxo Oncology Inc. FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2). Accessed November 26, 2018.
- 169
- Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer 2004;101(12):2755-9. PMID 15536625
- 170
- Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR-T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 2023;24(6):e255-69. PMID 37269857
- 171
- Ly KI, Arrillaga-Romany IC. Neurologic complications of systemic anticancer therapy. Neurol Clin 2018;36(3):627-51.** PMID 30072074
- 172
- Mahdi J, Dietrich J, Straathof K, et al. Tumor inflammation-associated neurotoxicity. Nat Med 2023;29(4):803-10.** PMID 37024595
- 173
- Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology 1998;12:63-76. PMID 9830635
- 174
- Masterson K, Merlini L, Lovblad KO. Coexistence of reversible cerebral neurotoxicity and irreversible cerebellar atrophy following an intrathecal methotrexate chemotherapy: two case reports. J Neuroradiol 2008;36(2):112-4. PMID 18722663
- 175
- Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010;36 Suppl 2:S24-32. PMID 20472185
- 176
- Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020;8(2):e001511. PMID 33335028
- 177
- McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8:10-6. PMID 19139108
- 178
- Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815-9. PMID 3095121
- 179
- Meyers CA, Obbens EA, Scheibel RS, et al. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991a;69:88-92. PMID 2049759
- 180
- Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991b;41:672-7. PMID 2027482
- 181
- Mielke S, Potthoff K, Feuerhake F, et al. Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation. Onkologie 2007;30(1-2):49-52. PMID 17264526
- 182
- Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42(1):24-30. PMID 16293411
- 183
- Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24(27):4507-14. PMID 16940275
- 184
- Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol 1983;12(6):365-9. PMID 6686617
- 185
- Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother 2000;34(10):1136-8. PMID 11054980
- 186
- Muller J, Kralovanszky J, Adleff V, et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res 2008;28:3051-4. PMID 19031955
- 187
- National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. Version 1.2020. Accessed December 16, 2020. http://www.jnccn.org.
- 188
- Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15(1):47-62. PMID 28925994
- 189
- Nelarabine. ARRANON (R) intravenous injection, nelarabine intravenous injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2018.
- 190
- New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel. Neurology 1996;46:108-11. PMID 8559355
- 191
- Newton HB, Page MA, Junck L, et al. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989;7:39-45. PMID 2547032
- 192
- Niemann B, Rochlitz C, Herrmann R, Pless M. Toxic encephalopathy induced by capecitabine. Oncology 2004;66(4):331-5. PMID 15218302
- 193
- Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999;5(3):501-6. PMID 10100699
- 194
- Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000;18(12):2385-94. PMID 10856098
- 195
- Ohara S, Hayashi R, Hata S, et al. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. Acta Neuropathologica 1998;96:527-31. PMID 9829818
- 196
- Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88. PMID 11208829
- 197
- Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004;10(2):461-7. PMID 14760066
- 198
- Openshaw H, Slatkin NE, Stein AS, Hinton DR, Forman SJ. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996;78(9):1899-1905. PMID 8909309
- 199
- Osborne WL, Holyoake TL, McQuaker IG, Parker AN. Fatal peripheral neuropathy following FLA chemotherapy. Clin Lab Haematol 2004;26(4):295-6. PMID 15279668
- 200
- Ostrow S, Hahn D, Wiernik PH, Richards RD. Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep 1978;62(10):1591-4. PMID 709562
- 201
- Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. New Engl J Med 2006;354(9):980-2. PMID 16514715
- 202
- Ozyurek H, Oguz G, Ozen S, et al. Reversible posterior leukoencephalopathy syndrome: report of three cases. J Child Neurol 2005;20(12):990-3. PMID 16417849
- 203
- Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52:791-5. PMID 19165892
- 204
- Paleologos N. Complications of chemotherapy. In: Biller J, editor. Iatrogenic neurology. Boston: Butterworth-Heinemann, 1998:439-60.
- 205
- Paleologos N, Nick NA. Corticosteroids in neuro-oncology. In: Schiff D, Wen PY, editors. Cancer neurology in clinical practice. Totowa: Humana Press, 2002:17-23.
- 206
- Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why. Crit Rev Oncol Hematol 2006;59(2):159-68. PMID 16806962
- 207
- Patel PN. Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother 2006;40(2):299-303. PMID 16391008
- 208
- Paterson AH, McPherson TA. A possible neurologic complication of DTIC. Cancer Treat Rep 1977;61:105-6. PMID 861957
- 209
- Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000;82:291-4. PMID 10646879
- 210
- Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996;46:1596-9. PMID 8649555
- 211
- Phillips PC, Reinhard CS. Antipyrimidene neurotoxicity: cytosine arabinoside and 5-fluorouracil. In: Rottenberg DA, editor. Neurological complications of cancer treatment. Boston: Butterworth-Heinemann, 1991:97-114.
- 212
- Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacol 2000;34:25-38. PMID 10669184
- 213
- Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007;69(6):573-81. PMID 17679676
- 214
- Plotkin SR, Wen PY. Neurologic complications of chemotherapy. Neurologic complications of cancer therapy. Neurol Clin 2003;21:279-318. PMID 12690653
- 215
- Postma TJ, van Groeningen CJ, Witjes RJ, et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 1998;38:69-75. PMID 9540059
- 216
- Pratt CB, Goren MP, Meyer WH, et al. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990;8:1399-401. PMID 2380760
- 217
- Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 2002;29(2):180-3. PMID 12035842
- 218
- Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. PMID 29162153
- 219
- Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9-17. PMID 11954874
- 220
- Rao S, Cunningham D, deGramant A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22(19):3950-7. PMID 15459217
- 221
- Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg 2002;37(4):203-5. PMID 12372914
- 222
- Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004;251(2):226-8. PMID 14991361
- 223
- Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113-20. PMID 16754936
- 224
- Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144(6):895-903. PMID 19170677
- 225
- Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004;15(4):347-50. PMID 15057138
- 226
- Riehl J, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964;14:961-7. PMID 14219204
- 227
- Riggs JE, Mansmann PT, Cook LL, et al. Fulminant CNS perivascular lymphocytic proliferation: association with sargramostim, a hematopoietic growth factor. Clin Neuropharmacol 1999;22:288-91. PMID 10516880
- 228
- Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Current Cancer Drug Targets 2005;5(6):421-44. PMID 16178817
- 229
- Robertson GL, Bhoopalam N, Zelkowitz LJ. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 1973;132:717-20. PMID 4356234
- 230
- Rodriguez L, Ribera JM, Batlle M, et al. Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine. Haematologica 2002;87(7):ECR26. PMID 12091141
- 231
- Rohatiner AZ, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983;47:419-22. PMID 6830692
- 232
- Rohr UP, Augustus S, Lasserre SF, Compton P, Huang J. Safety of bevacizumab in patients with metastases to the central nervous system. J Clin Oncol (Meeting Abstracts) 2009, 27.
- 233
- Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004;25:1688-95. PMID 15569732
- 234
- Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132-43. PMID 18690886
- 235
- Rosenblum MK, Delattre J, Walker RW, et al. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathologic study. J Neurooncol 1989;7:269-81. PMID 2795121
- 236
- Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational anti-microtubule agent. J Natl Cancer Inst 1990;82:1247-59. PMID 1973737
- 237
- Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 1994;12(9):1754-63. PMID 8083697
- 238
- Ruggiero R, Di Napoli R, Balzano N, et al. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management. Expert Rev Clin Pharmacol 2023;16(5):423-34. PMID 37144360
- 239
- Rutkove SB. An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a. Arch Neurol 1997;54:907-8. PMID 9236581
- 240
- Saif MW, Wood TE, McGee PJ, Diasio RB. Peripheral neuropathy associated with capecitabine. Anticancer Drugs 2004;15(8):767-71. PMID 15494638
- 241
- Saito B, Nakamaki T, Nakashima H, et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol 2007;82(4):304-6. PMID 16947320
- 242
- Saito T, Asai O, Dobashi N, et al. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia. J Infect Chemother 2006;12(3):148-51. PMID 16826348
- 243
- Salloum E, Khan KK, Cooper DL. Chlorambucil-induced seizures. Cancer 1997;79:1009-13. PMID 9041164
- 244
- Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018;8(8):958-71. PMID 29880584
- 245
- Saumoy M, Castells G, Escoda L, Mares R, Richart C, Ugarriza A. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002;43(2):433-6. PMID 11999583
- 246
- Savarese DM, Gordon J, Smith TW, et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. Cancer 1996;77(2):387-94. PMID 8625249
- 247
- Schachter S, Freeman R. Transient ischemic attack and adriamycin cardiomyopathy. Neurology 1982;32:1380. PMID 6890646
- 248
- Schick RM, Jolesz F, Barnes PD, Macklis JD. MR diagnosis of dural venous sinus thrombosis complicating L-asparaginase therapy. Comput Med Imaging Graph 1989;13:319-27. PMID 2743289
- 249
- Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009;6(10):596-603. PMID 19707193
- 250
- Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010;28(8):1294-300. PMID 20142601
- 251
- Seidel C, Hentschel B, Simon M, et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol 2013;260(3):847-55. PMID 23104124
- 252
- Selleri C, Pane F, Notaro R, et al. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukemia followed by ATRA-induced pseudotumour cerebri. Br J Haematol 1996;92:937-40. PMID 8616088
- 253
- Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009;27(30):4961-5. PMID 19752338
- 254
- Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26:71-7. PMID 10482196
- 255
- Shapiro WR, Green SB. Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg 1987;66:313-5. PMID 3543256
- 256
- Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81. PMID 1564540
- 257
- Sherman JH, Aregawi DG, Lai A, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009;73(22):1924-6. PMID 19949039
- 258
- Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;66:1117-23. PMID 2169332
- 259
- Slovin S, Clark W, Carles J, et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. JAMA Oncol 2018;4(5):702-6. PMID 29222530
- 260
- Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359-67. PMID 23549581
- 261
- Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997;15:833-9. PMID 9053511
- 262
- Spiegel RJ, Cooper PR, Blum RH, et al. Treatment of massive intrathecal overdose by ventriculolumbar perfusion. N Engl J Med 1984;311:386-8. PMID 6610829
- 263
- Stein ME, Drumea K, Yarnitsky D, et al. A rare event of 5-fluorouracil-associated peripheral neuropathy; a report of two patients. Am J Clin Oncol 1998;21:248-9. PMID 9626791
- 264
- Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol 2019;98(1):159-67. PMID 30238148
- 265
- Stewart DJ, Belanger G, Grahovac Z, et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 1992;30:512-7. PMID 1316564
- 266
- Stumpf PK, Cittelly DM, Robin TP, et al. Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4. Clin Cancer Res 2019;25(13):3946-53. PMID 30940654
- 267
- Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67. PMID 18567992
- 268
- Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996;2:477-81. PMID 9816193
- 269
- Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockage therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013;2013:857519. PMID 24278787
- 270
- Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8(5):387-94. PMID 17466895
- 271
- Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999;42(1):73-7. PMID 10360481
- 272
- Tlemsani C, Mir O, Boudou-Rouquette P, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011;6(4):253-8. PMID 22090260
- 273
- Tirelli U, Carbone A, Crivellari D, et al. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients. Cancer 1984;54(3):393-6. PMID 6375853
- 274
- Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74(3):212-6. PMID 15693790
- 275
- Treat J, Damjanov N, Huang C, Zrada S, Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Williston Park) 2001;15(5 Suppl 7):44-8. PMID 11396365
- 276
- Troy L, McFarland K, Littman-Power S, et al. Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology 2000;9(1):29-39. PMID 10668057
- 277
- Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003;15(7):435-9. PMID 14570094
- 278
- van den Bent MJ, Hilkens PH, Sillevis Smitt PA, et al. Lhermitte’s sign following chemotherapy with docetaxel. Neurology 1998;50:563-4. PMID 9484402
- 279
- van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine 2021;27(12):2099-2103. PMID 34893771
- 280
- Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulphan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7. PMID 2400986
- 281
- Vecht CJ, Verbiest HB. Use of glucocorticoids in neuro-oncology. In: Wiley RG, editor. Neurological complications of cancer. New York: Marcel Dekker, 1995:199-218.
- 282
- Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002;70(1):51-4. PMID 11994982
- 283
- Videnovic A, Semenor I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of 5 cases. Neurology 2005;65(11):1792-4. PMID 16237130
- 284
- Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000;18(6):1316-23. PMID 10715303
- 285
- Walker RW, Allen JC, Rosen G, et al. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4:1845-50. PMID 3465876
- 286
- Walker RW, Rosenblum MK, Kempin SJ, et al. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989;64:1017-20. PMID 2667747
- 287
- Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986;4:74-9. PMID 2416889
- 288
- Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 2006;242:47-54. PMID 16386273
- 289
- Weintraub M, Adde MA, Venzon DJ, et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996;14:935-40. PMID 8622042
- 290
- Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989;32(6):770-5. PMID 2735964
- 291
- Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985;3(12):1683-9. PMID 4067616
- 292
- Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011;22(4):991-3. PMID 21357649
- 293
- Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73(8):928-33. PMID 27271951
- 294
- Winkelman MD, Hines JD. Cerebellar degeneration caused by high dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983;14:520-7. PMID 6651239
- 295
- Winter SF, Jo J, Schiff D, Dietrich J. Central nervous system complications among oncology patients. Hematol Oncol Clin North Am 2022;36(1):217-36. PMID 34607715
- 296
- Winter SF, Martinez-Lage M, Clement NF, Hochberg EP, Dietrich J. Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy. Eur J Cancer 2021;144:178-81. PMID 33360262
- 297
- Winter SF, Vaios EJ, Dietrich J. Central nervous system injury from novel cancer immunotherapies. Curr Opin Neurol 2020;33(6):723-35. PMID 32941192
- 298
- Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94(4 Suppl):1349-57. PMID 11877765
- 299
- Wyllie AR, Bayliff CD, Kovacs MJ. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 1997;31:171-4. PMID 9034417
- 300
- Yamaji S, Kanamori H, Mishima A, et al. All-trans retinoic acid-induced multiple mononeuropathies. Am J Hematol 1999;60:311. PMID 10203107
- 301
- Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17(9):2762-71. PMID 10561351
- 302
- Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988;80:556-66. PMID 3286879
- 303
- Zhang Q, Zhu X, Xiao Y. The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Ann Hematol 2024;103(7):2197-206. PMID 38329486
- 304
- Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol 2006;36(3):205-12. PMID 16369780
- 305
- Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. Crit Rev Oncol Hematol 2015;95(3):359-69. PMID 25964164
- 306
- Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro Oncol 2018;20(1):24-36.** PMID 28992326
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Authors
-
Jörg Dietrich MD PhD MBA MMSc FAAN FANA
Dr. Dietrich of Harvard Medical School received consulting fees from Novartis and Johnson & Johnson.
See Profile -
Eudocia Quant Lee MD MPH
Dr. Lee of Harvard Medical School, Dana Farber Cancer Institute, and Brigham Women's Hospital has no relevant financial relationships to disclose.
See Profile -
Patrick Y Wen MD
Dr. Wen of Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital received consulting fees from Anheart and Tango for advisory board membership and research support from Servier.
See Profile
Editor
-
Rimas V Lukas MD
Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile
Former Authors
- Santosh Kesari MD PhD
- Jeanine Grier MD
Patient Profile
- Age range of presentation
-
- 2 to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity may be a factor
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Encephalitis, myelitis and encephalomyelitis, unspecified: G04.9
- Myelopathy NOS: G95.9
- Generalized idiopathic epilepsy and epileptic syndromes: G40.3
- Inflammatory polyneuropathy: G61
- Unconsciousness NOS: R40.2
- Headache: R51
- ICD-11
-
- Other specified disorders of the nervous system: 8E4Y
- Myelopathy: 8B42
- Chronic post cancer treatment pain: MG30.11
- Inflammatory polyneuropathy: 8C01
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuro-Oncology
Tumors of the skull base
Dec. 05, 2024
-
Neuro-Oncology
Ganglioglioma
Oct. 15, 2024
-
Neuro-Oncology
Paraneoplastic syndromes
Oct. 15, 2024
-
Neuro-Oncology
Overview of neuropathology updates for infiltrating gliomas
Oct. 11, 2024
-
Neuro-Oncology
NTRK-fused tumors of the central nervous system
Oct. 07, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Neuro-Oncology
Brain metastases
Oct. 03, 2024